Molecular Biology Resources, Inc.

www.molbiores.com

Founded in 1985 in Milwaukee, Wisconsin, Molecular Biology Resources, Inc. (MBR) has earned the reputation as a world leader in biochemical manufacturing. An early pioneer in the restriction endonuclease and polymerase market, MBR continues to help move the industry forward with our ever expanding product line of unique reagents and testing services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

ITOLERANCE TO COLLBORATE WITH LYGENESIS FOR JOINT RESEARCH

iTolerance | July 01, 2022

news image

iTolerance, Inc., an early-stage privately held regenerative medicine company developing technology to enable organoid, tissue, and cell therapy, announced entering into a joint collaboration with LyGenesis, Inc., a clinical-stage biotechnology company with an organ regeneration technology platform. The joint collaboration is aimed at evaluating the potential of iTOL-201, a product candidate being developed combining LyGenesis' LYG-LIV-100 liver cell therapy and iTolerance's SA FasL micr...

Read More

Cell and Gene Therapy, Industrial Impact

SCIENTIST.COM ANNOUNCES THE LAUNCH OF COMPLIANCE MOBILE APP FOR IOS

Scientist.com | February 02, 2023

news image

On February 1, 2023, Scientist.com, the biopharma industry's largest R&D marketplace, announced the release of a new iOS mobile app. The app provides a new, easy-to-use, on-the-go experience for purchase request approvals and compliance. In addition, iPhone users receive untethered notifications for accepting, delegating, and clarifying requests without needing to use their computers. The result is speedier approvals and fewer delays in scientific discovery. Scientist.co...

Read More

Cell and Gene Therapy

NEW STUDY HIGHLIGHTS CELL AVIDITY'S POWER TO PROVIDE INSIGHTS INTO THE ROBUSTNESS OF T CELL ACTIVATION

LUMICKS | March 24, 2022

news image

LUMICKS, a next generation life science tools company, today announced that a research study published in Cellular and Molecular Life Sciences from the Radboud University Medical Center, led by researchers in the team of Professor G. J. Adema, detailed a novel method to study lead compound effects on immune cell interactions by employing LUMICKS' z-Movi® Cell Avidity Analyzer. The interaction between dendritic cells (DCs) and T cells is a critical step in the activation of...

Read More

Industrial Impact

N-LOREM FOUNDATION PARTNERS WITH ARGONAUT TO MANUFACTURE ASO MEDICINES FOR PATIENTS WITH NANO-RARE DISEASES

Argonaut Manufacturing Services | February 02, 2022

news image

Argonaut Manufacturing Services, a leading contract manufacturing organization, and n-Lorem, a nonprofit foundation, today announced a new partnership that supports and reduces the cost of manufacturing of n-Lorem’s experimental antisense oligonucleotide medicines developed for nano-rare disease patients for free, for life. “Providing nano-rare patients, who would otherwise be largely ignored by our current drug discovery paradigm, with a personal...

Read More
news image

Cell and Gene Therapy

ITOLERANCE TO COLLBORATE WITH LYGENESIS FOR JOINT RESEARCH

iTolerance | July 01, 2022

iTolerance, Inc., an early-stage privately held regenerative medicine company developing technology to enable organoid, tissue, and cell therapy, announced entering into a joint collaboration with LyGenesis, Inc., a clinical-stage biotechnology company with an organ regeneration technology platform. The joint collaboration is aimed at evaluating the potential of iTOL-201, a product candidate being developed combining LyGenesis' LYG-LIV-100 liver cell therapy and iTolerance's SA FasL micr...

Read More
news image

Cell and Gene Therapy, Industrial Impact

SCIENTIST.COM ANNOUNCES THE LAUNCH OF COMPLIANCE MOBILE APP FOR IOS

Scientist.com | February 02, 2023

On February 1, 2023, Scientist.com, the biopharma industry's largest R&D marketplace, announced the release of a new iOS mobile app. The app provides a new, easy-to-use, on-the-go experience for purchase request approvals and compliance. In addition, iPhone users receive untethered notifications for accepting, delegating, and clarifying requests without needing to use their computers. The result is speedier approvals and fewer delays in scientific discovery. Scientist.co...

Read More
news image

Cell and Gene Therapy

NEW STUDY HIGHLIGHTS CELL AVIDITY'S POWER TO PROVIDE INSIGHTS INTO THE ROBUSTNESS OF T CELL ACTIVATION

LUMICKS | March 24, 2022

LUMICKS, a next generation life science tools company, today announced that a research study published in Cellular and Molecular Life Sciences from the Radboud University Medical Center, led by researchers in the team of Professor G. J. Adema, detailed a novel method to study lead compound effects on immune cell interactions by employing LUMICKS' z-Movi® Cell Avidity Analyzer. The interaction between dendritic cells (DCs) and T cells is a critical step in the activation of...

Read More
news image

Industrial Impact

N-LOREM FOUNDATION PARTNERS WITH ARGONAUT TO MANUFACTURE ASO MEDICINES FOR PATIENTS WITH NANO-RARE DISEASES

Argonaut Manufacturing Services | February 02, 2022

Argonaut Manufacturing Services, a leading contract manufacturing organization, and n-Lorem, a nonprofit foundation, today announced a new partnership that supports and reduces the cost of manufacturing of n-Lorem’s experimental antisense oligonucleotide medicines developed for nano-rare disease patients for free, for life. “Providing nano-rare patients, who would otherwise be largely ignored by our current drug discovery paradigm, with a personal...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us